NEW YORK (GenomeWeb) – Elucidata, a developer of analytics software to support drug discovery, has signed a four-year contract with startup biotech firm Auron Therapeutics to provide data analytics for differentiation-based cancer therapies. Financial terms were not disclosed.
Wellesley, Massachusetts-based Auron Therapeutics, which launched this year, will leverage Elucidata's cloud-based data analytics platform called Polly to to analyze transcriptomic, metabolomic, and epigenetic data from biological samples, the companies said. Auron is seeking to identify and validate targets for differentiation-based therapy for acute myeloid leukemia and eight other types of cancer.
"With our platform, we are seeking to develop an atlas of differentiation paths of healthy and diseased cells that will help us identify and characterize disease mechanisms," Elucidata Cofounder and CEO Abhishek Jha said in a statement. "This collaboration with Auron is an incredible opportunity to realize the promise of big-data analytics to discover new targets that will deliver more precise medicine to patients."
Cambridge, Massachusetts-based Elucidata raised $1.7 million in a seed funding round that closed in June.